Cargando…

Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry

BACKGROUND: Medication nonadherence can result in poor clinical outcomes and significant costs to health care providers. When treating venous thromboembolism (VTE), subtherapeutic anticoagulation may contribute to complications such as recurrent VTE or postthrombotic syndrome. OBJECTIVES: To describ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Speed, Victoria, Auyeung, Vivian, Patel, Jignesh P., Cooper, Derek, Miller, Stephen, Roberts, Lara N., Patel, Raj K., Arya, Roopen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606029/ https://www.ncbi.nlm.nih.gov/pubmed/34849447 http://dx.doi.org/10.1002/rth2.12614

Ejemplares similares

Rivaroxaban in acute venous thromboembolism: UK prescribing experience
por: Speed, Victoria, et al.
Publicado: (2021)

Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registry
por: Müller, Stephanie, et al.
Publicado: (2022)

The impact of body weight on rivaroxaban pharmacokinetics
por: Barsam, Sarah J., et al.
Publicado: (2017)

Anticoagulated patient’s perception of their illness, their beliefs about the anticoagulant therapy prescribed and the relationship with adherence: impact of novel oral anticoagulant therapy – study protocol for The Switching Study: a prospective cohort study
por: Auyeung, Vivian, et al.
Publicado: (2016)

Postdischarge venous thromboembolism following hospital admission with COVID-19
por: Roberts, Lara N., et al.
Publicado: (2020)

Associations between illness beliefs, medication beliefs, anticoagulation‐related quality of life, and INR control: Insights from the Switching Study
por: Bartoli‐Abdou, John K., et al.
Publicado: (2018)

Venous thromboembolism in patients hospitalised with COVID-19 in England
por: Roberts, Lara N., et al.
Publicado: (2022)

Rivaroxaban for cancer-associated venous thromboembolism
por: Liang, Bo, et al.
Publicado: (2021)

What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trial
por: Sayar, Zara, et al.
Publicado: (2019)

Testing the Traditional Chinese Medicine Consultation Model for Adherence in Complementary and Alternative Medicine
por: Ding, Amally, et al.
Publicado: (2020)

Mode of Delivery Does Not Influence Postpartum Hypercoagulability Measured by Thrombin Generation or Thromboelastometry
por: Guimicheva, Boriana, et al.
Publicado: (2020)

Fatigue after initiating rivaroxaban for venous thromboembolism
por: Karlsvik, Tina Margrethe, et al.
Publicado: (2020)

Changes in thrombin generation and D-dimer concentrations in women injecting enoxaparin during pregnancy and the puerperium
por: Patel, Jignesh P, et al.
Publicado: (2014)

Effect of type 1 diabetes and type 2 diabetes on the risk of venous thromboembolism
por: Hinton, William, et al.
Publicado: (2020)

Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic
por: Patel, Rachna, et al.
Publicado: (2021)

Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020)

How do anticoagulants impact menstrual bleeding and quality of life? - The PERIOD study
por: Patel, Jignesh P., et al.
Publicado: (2023)

Traditional Anticoagulants and Hair Loss: A Role for Direct Oral Anticoagulants? A Review of the Literature
por: Watras, Magdalena M., et al.
Publicado: (2016)

Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist
por: Bamber, Luke, et al.
Publicado: (2015)

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism
por: Harder, Sebastian
Publicado: (2014)

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

Factors influencing the recruitment of lactating women in a clinical trial involving direct oral anticoagulants: a qualitative study
por: Zhao, Yating, et al.
Publicado: (2018)

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)

Treatment with rivaroxaban and monitoring of coagulation profiles in two dogs with venous thromboembolism
por: UCHIDA, Mona, et al.
Publicado: (2020)

The “lived” experience of menstruating women commencing anticoagulants
por: Sheikh, Umber, et al.
Publicado: (2023)

New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban
por: Borris, Lars Carl
Publicado: (2008)

Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery
por: Du, Wei, et al.
Publicado: (2015)

Use of rivaroxaban in sickle cell disease and venous thromboembolism: A case report
por: Rozi, Waail, et al.
Publicado: (2021)

Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism
por: Reda, Sara, et al.
Publicado: (2022)

Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J’xactly study
por: Migita, Shohei, et al.
Publicado: (2023)

Rivaroxaban vs. warfarin for the treatment and prevention of venous thromboembolism: A meta-analysis
por: Liu, Zhuang, et al.
Publicado: (2023)

Thrombin Generation in Acute Ischaemic Stroke
por: Balogun, Ibrahim O., et al.
Publicado: (2016)

Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization
por: Hess, Connie N., et al.
Publicado: (2022)

Venous thromboembolism prophylaxis after total knee arthroplasty (TKA): aspirin vs. rivaroxaban()
por: Colleoni, Jose Luiz, et al.
Publicado: (2017)

Rivaroxaban for the treatment of venous thromboembolism in real life: A single-center prospective study
por: Demelo-Rodríguez, Pablo, et al.
Publicado: (2019)

Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer
por: Lee, Jang Ho, et al.
Publicado: (2019)

Rivaroxaban for cancer-associated venous thromboembolism: A systematic review and meta-analysis protocol
por: Liang, Bo, et al.
Publicado: (2019)

Oral Rivaroxaban Versus Standard Therapy in Acute Venous Thromboembolism Treatment for Vietnamese Patients
por: Bui, My Hanh, et al.
Publicado: (2019)

Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers
por: Lee, Jang Ho, et al.
Publicado: (2019)

Validation of venous thromboembolism diagnoses in patients receiving rivaroxaban or warfarin in The Health Improvement Network
por: Ruigómez, Ana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6ou53naiunccrltn2vque4ruuv